Recommendation of the President – Rozebalamin (mecobalamin)

On 27 February 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 16/2025 on the legitimacy of issuing approvals for the reimbursement of the medicinal product Rozebalamin (mecobalamin) for the indication: amyotrophic lateral sclerosis

Publication in Public Information Bulletin (BIP) >>